Therapeutically active pyrazolo-pyrimidine derivatives
AssigneesUcb Biopharma Srl, Katholieke Universiteit Leuven, KU LEUVEN R&D
InventorsDaniel James Ford, Richard Jeremy Franklin, Anant Ramrao Ghawalkar, Helen Tracey Horsley, Qiuya Huang, James Thomas Reuberson, Bart Vanderhoydonck
Life of this patent
Estimating the term…
Abstract
A series of pyrazolo[3,4-d]pyrimidine derivatives that are substituted at the 4-position by a diaza monocyclic, bridged bicyclic or spirocyclic moiety, are beneficial in the treatment and/or prevention of various human ailments, including inflammatory, autoimmune and oncological disorders; viral diseases and malaria; and organ and cell transplant rejection.
Claims12
A compound represented by formula (IA), or a pharmaceutically acceptable salt or solvate thereof:
- wherein R12 represents hydrogen, trifluoromethyl or C1-6 alkyl;
- Q is
- in which the asterisk (*) represents the point of attachment to the remainder of the molecule;
- Y represents —C(O)—, —C(O)N(R4)— or —C(O)C(O)—;
- Z represents C3-7 cycloalkyl, C3-7 heterocycloalkyl, aryl, or heteroaryl any of which groups is optionally substituted by one or more substituents independently selected from halogen, cyano, C1-6 alkyl, trifluoromethyl, (C3-7)-heterocycloalkyl, dihalo(C3-7)heterocycloalkyl, hydroxy, oxo, C1-6 alkoxy, difluoromethoxy, trifluoromethoxy, trifluoroethoxy, C1-6 alkylsulfonyl, C1-6 alkylamino and di(C1-6)alkylamino;
- A1 represents hydrogen, methyl, ethyl, isopropyl, isobutyl, trifluoromethyl, trifluoroethyl, —CH2ORa or —CH2CH2ORa;
- A2 represents hydrogen or C1-6 alkyl;
- R4 represents hydrogen or C1-6 alkyl;
- Ra represents hydrogen or C1-6 alkyl;
- and
- R13 represents C1-6 alkyl.
Dependencies are inferred from the claim text.